CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home »

ONCOLOGY. Vol. 15 No. 2
 

Study Contributes to Evolution of Sentinel Lymph Node Biopsy for Melanoma

February 1, 2001

Sentinel lymph node biopsy has rapidly evolved into the standard of care for node-negative melanoma. It has been used at the Roswell Park Cancer Institute (RPCI) since 1993, and through periodic reviews of results, several modifications have been made to improve outcomes and contribute to the evolution of sentinel lymph node biopsy. Michael S. Sabel, MD, and William G. Kraybill, MD, of RPCI’s department of surgery, and colleagues, reported on the latest such review in a recent issue of the journal, Surgery (128:556-563, 2000).

"Presently, there is great variation from hospital to hospital in the technique of intraoperative sentinel lymph node mapping," said Dr. Sabel. "Several aspects of the technique have changed and evolved since it was described initially in 1992. If sentinel lymph node biopsy is to be the standard of care, these improvements in technique must be disseminated so that it can be performed in a standardized manner," said Dr. Kraybill.

Nuclear Medicine and Pathology Improve Results

In the review, the charts of 182 patients with clinically node-negative primary cutaneous melanoma, who had undergone sentinel lymph node biopsy between January 1993 and December 1998 at RPCI, were reviewed and assessed for the technique used to identify the sentinel lymph node, pathologic evaluation, and use of the intraoperative frozen section. Results indicated that:

  • the accuracy of sentinel lymph node identification improved from 91% to 100% with the combination of isosulfan blue dye and radiolabeled colloid over isosulfan blue dye alone;

  • routine rather than selective lymphoscintigraphy identified seven in-transit sentinel lymph nodes and increased detection of dual basin drainage from 15% to 27%; and

  • identification of micrometastases in the sentinel lymph node increased from 14% to 24% after discontinuing the frozen section analysis of the sentinel lymph node in favor of processing tissue for permanent paraffin(Drug information on paraffin) sectioning with multiple hematoxylin and eosin levels and S-100 and HMB-45 immunochemistry evaluations.

"Through this careful review and strong collaboration with colleagues in nuclear medicine and pathology, several areas have been identified where sentinel lymph node biopsy may be improved," said Dr. Kraybill. "We believe this approach is necessary if the benefits of the technique for malignant melanoma are to be realized."

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
IMAGE IQ

Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
James B. Yu, MD1 , May 17, 2013

A 70-year-old man with a history of localized prostate cancer treated with whole-pelvis radiation therapy with a boost to the prostate, in conjunction with androgen deprivation therapy 7 years prior, presented with lower back pain. A bone scan revealed an area of activity in the sacrum. What is the most likely diagnosis?

More Image IQs 

 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Skin Lesions
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Colorectal Lesions
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Genomics Studies Identify Testicular Cancer Risk Variants
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • “This Is My Last Day on Earth”
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
  • Patient Quality of Life Endpoints in Oncology Trials, Part II
  • Who's Coding Whom?
  • “How Do I Say This Nicely? Your Oncologist Wasn't Following Guidelines”
  • Cancer Metabolism as a Therapeutic Target
  • Study: Cholesterol Drugs Reduced Risk of Prostate Cancer Death
  • “This Is My Last Day on Earth”
  • ONS: Safe Handling of Chemotherapy
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
Click here to subscribe to our newsletter



CancerNetwork on Facebook

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy